Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 05/30/2023.
  • Additional Information
    • Alternate Title:
      Janssen-FDA-NDA
    • Subject Terms:
      New Jersey
    • Abstract:
      This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease [ABSTRACT FROM PUBLISHER]